217 related articles for article (PubMed ID: 20205718)
1. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.
Asakawa H; Koizumi H; Koike A; Takahashi M; Wu W; Iwase H; Fukuda M; Ohta T
Breast Cancer Res; 2010; 12(2):R17. PubMed ID: 20205718
[TBL] [Abstract][Full Text] [Related]
2. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
4. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
[TBL] [Abstract][Full Text] [Related]
5. BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Schouten PC; Gluz O; Harbeck N; Mohrmann S; Diallo-Danebrock R; Pelz E; Kruizinga J; Velds A; Nieuwland M; Kerkhoven RM; Liedtke C; Frick M; Kates R; Linn SC; Nitz U; Marme F
Int J Cancer; 2016 Aug; 139(4):882-9. PubMed ID: 26946057
[TBL] [Abstract][Full Text] [Related]
6. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
Tiezzi DG; Andrade JM; Ribeiro-Silva A; Zola FE; Marana HR; Tiezzi MG
BMC Cancer; 2007 Feb; 7():36. PubMed ID: 17324279
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Watanabe Y; Maeda I; Oikawa R; Wu W; Tsuchiya K; Miyoshi Y; Itoh F; Tsugawa K; Ohta T
Genes Cells; 2013 Dec; 18(12):1120-30. PubMed ID: 24581343
[TBL] [Abstract][Full Text] [Related]
9. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
13. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.
Taucher S; Rudas M; Mader RM; Gnant M; Sporn E; Dubsky P; Roka S; Bachleitner T; Fitzal F; Kandioler D; Wenzel C; Steger GG; Mittlböck M; Jakesz R
Breast Cancer Res Treat; 2003 Dec; 82(3):207-13. PubMed ID: 14703068
[TBL] [Abstract][Full Text] [Related]
14. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.
Graeser M; McCarthy A; Lord CJ; Savage K; Hills M; Salter J; Orr N; Parton M; Smith IE; Reis-Filho JS; Dowsett M; Ashworth A; Turner NC
Clin Cancer Res; 2010 Dec; 16(24):6159-68. PubMed ID: 20802015
[TBL] [Abstract][Full Text] [Related]
15. Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
Takahashi Y; Miyoshi Y; Morimoto K; Taguchi T; Tamaki Y; Noguchi S
J Cancer Res Clin Oncol; 2007 Aug; 133(8):501-9. PubMed ID: 17297610
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer.
Mulligan JM; Hill LA; Deharo S; Irwin G; Boyle D; Keating KE; Raji OY; McDyer FA; O'Brien E; Bylesjo M; Quinn JE; Lindor NM; Mullan PB; James CR; Walker SM; Kerr P; James J; Davison TS; Proutski V; Salto-Tellez M; Johnston PG; Couch FJ; Paul Harkin D; Kennedy RD
J Natl Cancer Inst; 2014 Jan; 106(1):djt335. PubMed ID: 24402422
[TBL] [Abstract][Full Text] [Related]
19. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
[TBL] [Abstract][Full Text] [Related]
20. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
